Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

In a report released on January 3, Whit Mayo from Leerink Partners maintained a Buy rating on OceanPal Inc (OP – Research Report). The ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Align Technology (ALGN) been upgraded to outperform from market perform by Leerink Partners, citing potential profit upside. Read more here.

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of OmniAb in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now ...

D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. D. Boral ...

Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter profit and maintained its annual forecast on ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...